| Name | Oxford Biomedica |
|---|---|
| Epic | OXB |
| Isin | GB00BDFBVT43 |
| Index | UK250 UK350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 666.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £802.51 | Debt ratio | n/a |
| Shares in issue | 120.21 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -26.52 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -41.75 | 52-week high / low | 232.50p / 670.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Oxford Biomedica |
|---|---|
| Address | Windrush Court, Transport Way, Oxford, United Kingdom, OX4 6LT |
| Telephone | +44 (0) 1865 783 000 |
| Website | http://www.oxb.com/ |
| Director | Position |
|---|---|
| Dr Frank Mathias | CEO |
| Mr Lucinda (Lucy) Crabtree | CFO |
| Dr Roch Doliveux | Chairman |
| Mr Colin Bond | Non-Executive Director |
| Mr Peter Soelkner | Non-Executive Director |
| Ms Laurence Espinasse | Non-Executive Director |
| Mr Dame Kay Davies | Senior Independent Director |
| Dr Heather Preston | Independent Non-Executive Director |
| Ms Namrata P Patel | Independent Non-Executive Director |
| Assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 31/12/24 | 31/12/23 | 31/12/22 |
| Intangible asssets and goodwill | 29.22 | 30.98 | 105.89 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 98.45 | 111.01 | 244.68 |
| Inventory / work in progress | 13.57 | 12.87 | 12.62 |
| Trade and other receivables | 58.97 | 24.74 | 61.59 |
| Cash and equivalents | 60.65 | 103.72 | 141.28 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 231.64 | 252.34 | 460.18 |
| Liabilities £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 58.32 | 44.31 | 59.66 |
| Long term liabilities | 112.84 | 130.19 | 164.32 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 171.16 | 174.51 | 223.99 |
| Net assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | 60.49 | 77.83 | 236.19 |
| Equity £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 52.98 | 48.4 | 48.13 |
| Minority interests | 3.44 | 3.83 | 31.54 |
| Retained earnings | -399.5 | -352.92 | -198.54 |
| Share premium account | 394.86 | 380.33 | 379.95 |
| Total equity | 60.49 | 77.83 | 236.19 |
| Income £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -39.38 | -184.17 | -30.22 |
| Pre-tax profit | -47.27 | -188.53 | -45.98 |